Why the study?
Non-obstructive myocardial stunning is increasingly recognized but remains a diagnostic and therapeutic challenge in cardiology.
Answers are grounded in this paper and cite their sources.
Metabolic modulation with antimetabolic and anti-ischemic agents represents a potential emerging therapeutic avenue for managing non-obstructive myocardial stunning.
Non-obstructive myocardial stunning is characterized by transient myocardial contractile dysfunction despite preserved coronary perfusion. Although increasingly recognized, it remains a diagnostic and therapeutic challenge in cardiology. This review synthesizes current insights into reversible cardiomyopathies, explores the potential of antimetabolic and anti-ischemic agents in their management, and highlights emerging therapeutic avenues. Greater understanding of these mechanisms may improve patient outcomes in this underexplored area.
No takes yet. Share an insight, caveat, or question.
Özkan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: